Niraparib (Zejula; GSK) plus abiraterone acetate and prednisone (AAP) reduced the risk of cancer progression by 37% compared with AAP alone in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination…
Novel Drug Combo Improves Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer
